Controlling shareholder Tang Capital makes cash offer for LianBio
- LianBio receives unsolicited buyout offer from Concentra Biosciences
- Offer includes $4.30 in cash per share and contingent value rights
- Tang Capital, a minority shareholder, owns Concentra Biosciences
- Deal would require at least $515 million in cash and equivalents
- LianBio conducting strategic review in conjunction with Bristol Myers deal
LianBio, a biotechnology company, has received an unsolicited buyout offer from Concentra Biosciences, owned by LianBio minority shareholder Tang Capital. The offer includes $4.30 in cash per share of the company and a contingent value right representing rights to 80% of proceeds from any license or disposition of LianBio’s programs. Concentra, if the deal goes through, would acquire 100% of LianBio’s equity. However, the deal is subject to due diligence and would require at least $515 million in cash and equivalents to be available at closing. LianBio reported cash and cash equivalents of $103.5 million in the quarter ended Sept. 30, but expects to earn $350 million from the termination of an agreement with Bristol Myers Squibb. LianBio is currently conducting a strategic review in conjunction with the Bristol Myers deal.
Public Companies: LianBio (null), Concentra Biosciences (null), Bristol Myers Squibb (null)
Private Companies: Tang Capital
Key People: Ben Glickman ()
Factuality Level: 8
Justification: The article provides specific details about the unsolicited buyout offer from Concentra Biosciences to LianBio, including the offer price, the ownership relationship between Tang Capital and Concentra, and the percentage of LianBio’s equity that would be acquired. It also mentions the requirement for cash and equivalents at closing and provides information about LianBio’s cash and cash equivalents as of September 30 and the termination of an agreement with Bristol Myers Squibb. The article does not contain any obvious bias or opinion masquerading as fact.
Noise Level: 7
Justification: The article provides relevant information about LianBio receiving an unsolicited buyout offer from Concentra Biosciences. It includes details about the offer, the ownership structure, and the financial requirements of the deal. However, it lacks analysis, scientific rigor, and actionable insights. The article also briefly mentions a previous agreement with Bristol Myers Squibb, which seems unrelated to the main topic.
Financial Relevance: Yes
Financial Markets Impacted: The buyout offer from Concentra Biosciences to acquire LianBio may impact the financial markets and companies involved in the biotechnology industry.
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article discusses a potential buyout offer in the biotechnology industry, which can have financial implications. However, there is no mention of any extreme events or their impact.
www.marketwatch.com 
